# Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin

> **NCT05819125** · — · TERMINATED · sponsor: **Sanofi** · enrollment: 21000 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05819125
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2023-04-25
- **Primary completion:** 2023-12-15
- **Final completion:** 2023-12-15
- **Target enrollment:** 21000 (ACTUAL)
- **Why stopped:** Sponsor's decision. Termination decision unrelated to safety profile.
- **Last updated:** 2024-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05819125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05819125, "Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05819125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*